ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Viking Therapeutics Inc

Viking Therapeutics Inc (VKTX)

38,12
0,25
( 0,66% )
Aktualisiert: 17:58:55

Viking Therapeutics Inc (VKTX) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
38,12
( 0,66% )
Gebot
38,07
Fragen
38,17
Volumen
2.130.644
37,65 Tagesbereich 39,45
22,959 52-Wochen-Bereich 43,15
Marktkapitalisierung
Handelsende
37,87
Handelsbeginn
38,00
Letzter Handelszeitpunkt
17:59:29
Finanzvolumen
US$ 82.447.456
VWAP
38,696
Durchschnittliches Volumen (3 Mio.)
US$ 2.259.513
Ausgegebene Aktien
116.105.643
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-8,37
Gewinn pro Aktie (EPS)
-4,16
Erlöse (LTM)
-
Nettogewinn (LTM)
-472,34M

Über Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß),... Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
San Diego, United States
Gegründet
2026
Viking Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker VKTX. The last closing price for Viking Therapeutics was US$37,87. Over the last year, Viking Therapeutics shares have traded in a share price range of US$ 22,959 to US$ 43,15.

Viking Therapeutics currently has 116.105.643 shares in issue. The market capitalisation of Viking Therapeutics is US$4,43 billion. Viking Therapeutics has a price to earnings ratio (PE ratio) of -8.37.

Option-Flow Viking Therapeutics (VKTX)

Gesamtfluss

Bullisch

Nettoprämie

4M

Calls / Puts

5.300,00%

Käuf. / Verkä.

104,17%

OTM / ITM

58,82%

Sweeps

0,00%

VKTX Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
17.6325.024598228930.4939.4530.1614462728934.48152988CS
46.1519.236784485531.9739.4527.16248590931.48716037CS
126.0218.75389408132.139.4527.16228875932.06851302CS
260.872.335570469837.2539.4525.77263840532.09398603CS
5211.0140.612320177127.1143.1522.959386230331.30152183CS
15617.8287.783251231520.399.39998.28379710440.85167122CS
26031.73496.5571205016.3999.39992.02299571333.53158484CS

VKTX - Frequently Asked Questions (FAQ)

What is the current Viking Therapeutics Inc share price?
The current share price of Viking Therapeutics Inc is US$ 38,12
How many Viking Therapeutics Inc shares are in issue?
Viking Therapeutics Inc has 116.105.643 shares in issue
What is the market cap of Viking Therapeutics Inc?
The market capitalisation of Viking Therapeutics Inc is USD 4,43B
What is the 1 year trading range for Viking Therapeutics Inc share price?
Viking Therapeutics Inc has traded in the range of US$ 22,959 to US$ 43,15 during the past year
What is the PE ratio of Viking Therapeutics Inc?
The price to earnings ratio of Viking Therapeutics Inc is -8,37
What is the registered address of Viking Therapeutics Inc?
The registered address for Viking Therapeutics Inc is 9920 Pacific Heights Boulevard, San Diego, California, 92121
What is the Viking Therapeutics Inc website address?
The website address for Viking Therapeutics Inc is www.vikingtherapeutics.com
Which industry sector does Viking Therapeutics Inc operate in?
Viking Therapeutics Inc operates in the Biotechnology & Life Sciences sector

VKTX Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen